lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2

Cao, Yiqiang; Chai, Wenying; Wang, Yonggang; Dang, Tang; Shao, Dong-Chuan; Song, Hai Zhen; Jiang, Long

doi:10.3892/mmr.2021.12172

Cited by 20 publications

(5 citation statements)

References 44 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A172 glioma cells resistant to temozolomide also represent higher CSC-like properties compared to parental cells. The silencing of TUG1 or overexpression of EZH2 enhances CSC-like properties and resistance to temozolomide in A172 glioma cells [192]. EZH2 is a key epigenetic regulator that is suggested to be dysregulated in specific BC types, particularly in advanced stages [193,194].…”

Section: Regulation Of Cancer Stemness By Lncrna In Chemoresistant Bc...mentioning

confidence: 99%

Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA

Ahmadpour,

Orre,

Bertevello

et al. 2023

IJMS

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are a subclass of noncoding RNAs composed of more than 200 nucleotides without the ability to encode functional proteins. Given their involvement in critical cellular processes such as gene expression regulation, transcription, and translation, lncRNAs play a significant role in organism homeostasis. Breast cancer (BC) is the second most common cancer worldwide and evidence has shown a relationship between aberrant lncRNA expression and BC development. One of the main obstacles in BC control is multidrug chemoresistance, which is associated with the deregulation of multiple mechanisms such as efflux transporter activity, mitochondrial metabolism reprogramming, and epigenetic regulation as well as apoptosis and autophagy. Studies have shown the involvement of a large number of lncRNAs in the regulation of such pathways. However, the underlying mechanism is not clearly elucidated. In this review, we present the principal mechanisms associated with BC chemoresistance that can be directly or indirectly regulated by lncRNA, highlighting the importance of lncRNA in controlling BC chemoresistance. Understanding these mechanisms in deep detail may interest the clinical outcome of BC patients and could be used as therapeutic targets to overcome BC therapy resistance.

show abstract

Section: Regulation Of Cancer Stemness By Lncrna In Chemoresistant Bc...mentioning

confidence: 99%

Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA

Ahmadpour,

Orre,

Bertevello

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Furthermore, lncRNA CACS2 acts as a ceRNA molecule to reverse the resistance of tumour cells to TMZ, primarily through the miR-193a-5p/mTOR signalling pathway-mediated inhibition of autophagy. The results of in vivo and in vitro experiments indicated that lncRNA taurine upregulated gene 1 inhibits the EMT process and GSC phenotype of gliomas by downregulating the expression of enhancer of zeste homologue 2 (EZH2), thereby reducing TMZ resistance ( 126 ). In addition, lncRNAs have been indicated to affect the apoptosis of TMZ-resistant glioma cells.…”

Section: Lncrnas and Glioma Drug Resistancementioning

confidence: 99%

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

et al. 2022

View full text Add to dashboard Cite

As the most common primary tumour of the central nervous system, gliomas have a high recurrence rate after surgical resection and are resistant to chemotherapy, particularly high-grade gliomas dominated by glioblastoma multiforme (GBM). The prognosis of GBM remains poor despite improvements in treatment modalities, posing a serious threat to human health. At present, although drugs such as temozolomide, cisplatin and bevacizumab, are effective in improving the overall survival of patients with GBM, most patients eventually develop drug resistance, leading to poor clinical prognosis. The development of multidrug resistance has therefore become a major obstacle to improving the effectiveness of chemotherapy for GBM. The ability to fully understand the underlying mechanisms of chemotherapy resistance and to develop novel therapeutic targets to overcome resistance is critical to improving the prognosis of patients with GBM. Of note, growing evidence indicates that a large number of abnormally expressed noncoding RNAs (ncRNAs) have a central role in glioma chemoresistance and may target various mechanisms to modulate chemosensitivity. In the present review, the roles and molecular mechanisms of ncRNAs in glioma drug resistance were systematically summarized, the potential of ncRNAs as drug resistance markers and novel therapeutic targets of glioma were discussed and prospects for glioma treatment were outlined. ncRNAs are a research direction for tumor drug resistance mechanisms and targeted therapies, which not only provides novel perspectives for reversing glioma drug resistance but may also promote the development of precision medicine for clinical diagnosis and treatment.

show abstract

“… 290 TUG1 ↓ EZH2 in vitro , in vivo Cao et al. 291 HOXB-AS1 ↑ – in vitro Shao et al. 292 H19 ↑ – in vitro , in vivo , human Jiang et al.…”

Section: Introductionmentioning

confidence: 99%

“… 340 TUG1 lncRNA alleviated TMZ resistance and inhibited tumorigenicity downregulating EZH2 expression Cao et al. 291 SNHG9 lncRNA facilitates growth of GSCs competitive endogenous RNA of miR-326 to elevate the expression of SOX9 Wang et al. 341 RP11-279C4.1 lncRNA functions as an oncogene that promotes tumour progression modulating the miR-1273g-3p/CBX3 axis Wang et al.…”

Section: Introductionmentioning

confidence: 99%